As at May 12, 2025, the ABBV stock has a PE ratio of 80.54. This is based on the current EPS of $2.36 and the stock price of $190.07 per share. An increase of 12% has been seen in the P/E ratio compared to the average of 72.1 of the last 4 quarters.
The mean historical PE ratio of AbbVie over the last ten years is 31.15. The current 80.54 PE ratio is 159% above the historical average. Over the past ten years, ABBV's PE ratio was at its highest in the Mar 2025 quarter at 88.78, with a price of $209.52 and an EPS of $2.36. The Mar 2020 quarter recorded the bottom point at 13.44, with a price of $76.19 and an EPS of $5.67.
Maximum annual increase: 187.98% in 2014
Maximum annual decrease: -68.09% in 2015
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 74.04 | 30.42% | $177.7 | $2.4 |
2023 | 56.77 | 133.62% | $154.97 | $2.73 |
2022 | 24.3 | 16.27% | $161.61 | $6.65 |
2021 | 20.9 | -46.75% | $135.4 | $6.48 |
2020 | 39.25 | 134.89% | $107.15 | $2.73 |
2019 | 16.71 | -33.48% | $88.54 | $5.3 |
2018 | 25.12 | -14.03% | $92.19 | $3.67 |
2017 | 29.22 | 70.28% | $96.71 | $3.31 |
2016 | 17.16 | -8.77% | $62.62 | $3.65 |
2015 | 18.81 | -68.09% | $59.24 | $3.15 |
2014 | 58.95 | 187.98% | $65.44 | $1.11 |
2013 | 20.47 | N/A | $52.81 | $2.58 |
2012 | N/A | N/A | N/A | $3.35 |
2011 | N/A | N/A | N/A | $2.18 |
2010 | N/A | N/A | N/A | $2.65 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Mar 2025 | 88.78 | 19.91% | $209.52 | $2.36 |
Dec 2024 | 74.04 | 7.98% | $177.7 | $2.4 |
Sep 2024 | 68.57 | 19.94% | $197.48 | $2.88 |
Jun 2024 | 57.17 | 5.79% | $171.52 | $3 |
Mar 2024 | 54.04 | -4.81% | $182.1 | $3.37 |
Dec 2023 | 56.77 | 39.38% | $154.97 | $2.73 |
Sep 2023 | 40.73 | 47.52% | $149.06 | $3.66 |
Jun 2023 | 27.61 | -26.2% | $134.73 | $4.88 |
Mar 2023 | 37.41 | 53.95% | $159.37 | $4.26 |
Dec 2022 | 24.3 | 36.36% | $161.61 | $6.65 |
Sep 2022 | 17.82 | -17.5% | $134.21 | $7.53 |
Jun 2022 | 21.6 | -6.86% | $153.16 | $7.09 |
Mar 2022 | 23.19 | 10.96% | $162.11 | $6.99 |
Dec 2021 | 20.9 | -19.58% | $135.4 | $6.48 |
Sep 2021 | 25.99 | -15.31% | $107.87 | $4.15 |
ABBV's current P/E ratio is above the 3, 5 and 10-year historical averages.
ABBV's PE ratio is higher than its peer stocks LLY and AZN. AbbVie's current PE ratio of 80.54 is above the average of its peers, which is 27.74.
Stock name | PE ratio | Market cap |
---|---|---|
BIIB Biogen Inc | 12.24 | $18.23B |
PFE Pfizer Inc | 16.61 | $131.28B |
BMY Bristol Myers Squibb Co | 17.98 | $98.05B |
GILD Gilead Sciences Inc | 21.77 | $129.14B |
AMGN Amgen Inc | 24.87 | $147.74B |
AZN Astrazeneca plc | 27.47 | $213.75B |
NBIX Neurocrine Biosciences Inc | 39.75 | $11.92B |
LLY ELI LILLY & Co | 61.23 | $716.08B |
ABBV AbbVie Inc | 80.54 | $335.74B |
As of May 12, 2025, ABBV stock has a price to earnings ratio of 80.54.
The average PE ratio for ABBV stock over the past 3 years is 47.4.
The average PE ratio for ABBV stock over the past 5 years is 39.34.
Over the last ten years, the quarterly PE ratio reached a historic high of 88.78 in the Mar 2025 quarter.
ABBV's current price to earnings ratio is 159% above its 10-year historical average.
A company with a higher PE ratio may indicate that the market has higher growth expectations for the company's future earnings or profitability.
The PE ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (May 12, 2025), AbbVie's stock price is $190.07. The earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $2.36. Therefore, AbbVie's P/E ratio for today is 80.54. PE RATIO(80.54) = STOCK PRICE($190.07) / TTM EPS($2.36)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.